# Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)

> **NCT04138381** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Grupo Espanol de Investigacion en Sarcomas** · enrollment: 30 (actual)

## Conditions studied

- Maximum Tolerated Dose
- GIST
- Metastatic Adult Soft Tissue Sarcoma
- Drug Toxicity
- Drug Use

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT04138381
- **Lead sponsor:** Grupo Espanol de Investigacion en Sarcomas
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-16
- **Primary completion:** 2023-04-16
- **Final completion:** 2023-04-16
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04138381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04138381, "Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04138381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*